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Abstract
Aim. Multiorgan dysfunction is often encountered in jaundiced patients and may compromise the postoperative outcome
after liver resection for cholangiocarcinoma (CCA). The aim of the present study was to elucidate evidence-based medicine
regarding the benefit of the available preoperative treatments currently used for the preparation of patients before surgery
for hilar CCA. Material and methods. An electronic search using the Medline database was performed to identify relevant
articles relating to renal dysfunction, bacterial translocation, hemostasis impairment, malnutrition, liver failure, and
postoperative outcome in jaundiced patients undergoing liver resection for CCA. Results. There is grade B evidence to
expand the extracellular water volume and to administer oral synbiotic supplements. Intravenous vitamin K administration
is an effective treatment. Perioperative nutritional support should be administered preferably by the enteral route in severely
malnourished patients with compromised liver function undergoing extended liver resection (grade A evidence). There is
only grade C evidence to recommend a portal vein embolization in patients with CCA when the future remnant liver volume
is B40%. Conclusions. A simplified scheme that might be useful in the management of patients presenting with obstructive
jaundice was presented. Despite surgical technique improvements, preparation of patients for surgery will continue to be
one of the major determinants for the postoperative prognosis of jaundiced patients.
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Introduction
The current standard treatment of hilar cholangio-
carcinoma (CCA) is major hepatectomy combined
with extrahepatic procedures that include lymphade-
nectomy, extrahepatic bile duct resection, and, some-
times, portal vein resection [1]. Belghiti et al., in
evaluating the operative risk in 747 patients under-
going liver resection [2], observed that the mortality
rate was significantly higher in patients with jaundice
(21%) compared to that in cirrhotic patients (8.7%)
or in patients with normal liver (1%; pB0.001). They
also demonstrated that a combined extrahepatic
procedure was the only independent predictor of in-
hospital death in patients with malignancy. Several
related abnormalities resulting from obstructive jaun-
dice represent a kind of multiorgan failure and include
bacterial translocation [36], hemostasis impairment
[7], renal insufficiency [8], and increased risk of liver
failure [1,9]. Patient preparation before surgery for
CCA should therefore be focused on prevention of: 1)
bacteremia, 2) malnutrition, 3) hemostasis impair-
ment, 4) renal insufficiency, and, finally, 5) liver
failure. The role of preoperative biliary drainage will
be discussed in another lecture.
Prevention of bacteremia
The etiopathogeny of bacterial translocation in pa-
tients with obstructive jaundice is multifactorial. It
includes increased intestinal permeability [5], im-
paired clearance of endotoxins by Kupfer’s cell [4],
and altered systemic immunity [3,6]. The risk of
postoperative bacteremia has been evaluated in a large
series of 407 patients who underwent liver resection
[10], the authors showing that the risk of bacteremia
was significantly higher in patients with CCA (19%)
compared to the risk in those with hepatocellular
carcinoma (4%) or liver metastases (3%; pB0.0001).
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The multivariate analysis showed that the presence
of an obstructive jaundice increased the risk of
bacteremia by 4.6% and the performance of an
extended hepatectomy by 2.5%, indicating that the
bacteremic risk is increased 13 times in patients with
obstructive jaundice and undergoing an extended
hepatectomy for hilar cholagiocarcinoma [10].
Furthermore, the postoperative complications were
significantly associated with the occurrence of bacter-
emia, particularly liver failure, renal dysfunction, and
mortality [10]. The benefit of perioperative synbiotic
(lactobacillus and bifidobacterium) treatment was
recently analyzed in a prospective randomized trial
[11]. In patients receiving synbiotic therapy during
the perioperative period, the authors registered a
significant reduction in the postoperative infectious
complications rate, shorter hospital stay, and reduced
length of antibiotic therapy compared to that in
patients receiving synbiotic therapy only in the post-
operative period [11]. They also demonstrated that
perioperative synbiotic treatment enhanced the im-
mune responses, attenuated the systemic postopera-
tive inflammatory reaction, improved the intestinal
microbial environment, and reduced the postopera-
tive infectious complications rate [11].
Prevention of malnutrition
During the past decade, most of the relevant progress
achieved in the field of liver resection concerns a
better understanding of hepatic function and of the
metabolic needs of the liver during the perioperative
period. The aims of perioperative nutritional support
are to reduce the catabolic response, to improve
protein synthesis, to accelerate liver regeneration, to
decrease the damage of the residual liver, and to
reduce postoperative morbidity [12]. No reported
series has analyzed the effect of perioperative nutri-
tional support in patients with hilar CCA. Indeed, in
1994 the first randomized study evaluated the effect of
perioperative branched-chain amino-acids (valine,
leucine, isoleucine) therapy in cirrhotic patients with
hepatocellular carcinoma [13]. In patients receiving
branched-chain amino-acids nutritional support, the
authors observed a reduced rate of overall post-
operative morbidity (34% vs 55%) particularly septic
complications (17% vs 37%) and an improved post-
operative liver function as reflected by less deteriora-
tion of the indocyanin green test (ICG-R15) [13].
The same conclusions were reported in another recent
series using a similarly enriched diet [14]. Concerning
immunonutrition (arginine, omega-3 fatty acids), a
prospective randomized study has shown that perio-
perative enteral immunonutrition is associated with a
lower rate of overall postoperative complications in
patients undergoing surgery for malignant diseases
(9% vs 21% in the control group; p0.02) [15].
Prevention of hemostasis impairment
Vitamin K deficiency due to intestinal malabsorption
and impaired production of coagulation factors are
often encountered in patients with obstructive jaun-
dice [7].
Prevention of renal insufficiency
The etiology of renal insufficiency in patients with
obstructive jaundice is multifactorial, including extra-
cellular water depletion, myocardial dysfunction, in-
creased plasma levels of atrial natriuretic peptide
(ANP), and water and sodium retaining hormones
(aldosterone, renin, vasopressin, endothelin ET-1,
prostaglandin PGE2) [16]. A multivariate analysis
has shown that the predictors of renal insufficiency
in patients with obstructive jaundice are age, serum
bilirubin level, renin activity, endothelin (ET-1),
prostaglandin (PG E2), and urinary sodium excretion,
indicating that renal insufficiency is influenced by the
intensity of biliary obstruction, by the degree of
extracellular water depletion, and by the balance of
vasoactive and sodium-water regulating hormones.
However, the type (malignant or benign) and location
of the bile duct tumor (perihilar or extrahepatic) does
not influence the occurrence of renal insufficiency
[16]. In a prospective randomized clinical trial, the
benefit of extracellular water volume expansion was
evaluated in patients with obstructive jaundice under-
going endoscopic drainage [17]. The authors noticed
a significant improvement of the creatinine clearance
after intravenous fluid administration before any
procedure [17]. However, extracellular water expan-
sion failed to improve renal function after endoscopic
drainage. These observations are further evidence that
the etiopathogeny of renal insufficiency in patients
presenting with jaundice is multifactorial.
Prevention of liver failure
Two main factors affecting the occurrence of post-
operative liver failure after liver resection are the
future remnant liver volume and the quality of the
liver parenchyma. While several studies have shown
that portal vein embolization is effective in inducing
hypertrophy of the non-embolized liver [1821], the
benefit of portal vein embolization has not been
definitively validated in a randomized controlled trial.
Indeed, a prospective non-randomized study has
shown no benefit of portal vein embolization before
right hepatectomy in patients with normal underlying
liver parenchyma [22]. However, another series has
shown that portal vein embolization before an ex-
tended hepatectomy is justified when the estimated
future remnant liver volume is B25% [23]. In our
experience of portal vein embolization performed in
146 patients when the future remnant liver volume
was less than 30% of the total functional liver volume,
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the time required to obtain an adequate liver hyper-
trophy was shorter in patients with normal liver
[24]. Abdalla et al. noticed that the future remnant
liver volume correlated with postoperative outcome
[21]. They showed significantly higher complication
rates in patients with a future remnant liver volume
of B20% [21].
Only two retrospective studies focused on portal
vein embolization and biliary cancers [25,26]. The
largest series reported 240 consecutive patients un-
dergoing portal vein embolization before an extended
hepatectomy for biliary cancer with a mortality rate of
9% [26]. Underlining an improvement in the mortal-
ity rate over the study periods, i.e. changing from
17.9% between 1991 and 1995 to 4.8% after 2001,
the authors performed portal vein embolization when
the future remnant liver volume was B40%. The
second retrospective series showed neither mortality
nor liver failure with 40% 5-year survival in 58
patients who underwent extended hepatectomy for
hilar CCA [25]. These good results might be ex-
plained by a higher cut-off in the decision to perform
portal vein embolization. Indeed, if, in jaundiced
patients, the liver volume to be resected was more
than 50%, the authors performed portal vein embo-
lization before surgery. Then, after adequate liver
regeneration, liver resection was achieved only when
the total bilirubin level was more than twice the upper
normal limit. In the absence of jaundice, the decision
to perform hepatectomy was based on the liver
function test estimated by the ICG-R15. In patients
with normal ICG-R15 (510%), portal vein emboliza-
tion was performed when the future remnant liver
volume was B40%. However, for patients with
abnormal ICG-R15 test (10%), portal vein embo-
lization was performed when the future remnant liver
volume was B50% of the total functional liver
volume. In accordance with all the above reported
series, where should the volumetric cut-off be for
performing portal vein embolization in patients with
jaundice due to hilar CCA? No evidence-based
answer can be drawn from the literature, but the
following several factors should be considered when
deciding on portal vein embolization: 1) the ratio of
future remnant liver/total liver volume, 2) the pre-
sence of any underlying liver parenchyma injury
(particularly cholestasis), 3) the presence of comor-
bidities (diabetes mellitus and/or malnutrition which
inhibit liver regeneration), and 4) the necessity of a
combined extrahepatic procedure.
Consensus statements
. There is a benefit of preoperative oral adminis-
tration of synbiotic treatment in jaundiced
patients scheduled to undergo extended hepa-
tectomy combined with extrahepatic procedures.
. Perioperative nutritional support is indicated for
patients with severe malnutrition, with preopera-
tive compromised liver function, and undergoing
extended liver resection. Branched-chain amino-
acids immunonutrition should be administered
preferably by the enteral route beginning one
week before surgery.
. Intravenous vitamin K administration is an
effective treatment.
. There is a need to expand the extracellular water
volume in the preoperative period.
. Portal vein embolization is a key procedure in the
preoperative management of patients with hilar
CCA; it allows indications for liver resection to
be extended safely and the resection margins in a
curative intent increased. Portal vein emboliza-
tion is recommended in patients with CCA when
the future remnant liver volume is B40%. Liver
resection should not be performed earlier than
3 weeks after portal vein embolization.
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